Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, March 13, 2012

Medical Technology Stock Alert; PositiveID Corporation's (OTCBB:PSID) M-BAND Well Positioned for $3 Billion BioWatch Contract

DELRAY BEACH, Fla. - March 13, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), a developer of molecular diagnostic systems for bio-threat detection, announced today that its M-BAND (Microfluidic-Bioagent Autonomous Networked Detector) system is well positioned to take part in the Department of Homeland Security's ("DHS") $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS Science and Technology ("S&T") BAND Program. PositiveID's patented M-BAND biodetector was developed under a competitive award from DHS S&T, and M-BAND was the only successful system to emerge from the BAND program.

M-BAND, protected by United States Patent No. 7,705,739 B2 for an Integrated Airborne Substance Collection and Detection System, was developed by PositiveID's Microfluidic Systems ("MFS") subsidiary under six years of funding from the federal government.

M-BAND is a bioaerosol monitor with fully integrated modular systems including sample collection, purification and detection modules. Each module is independently functional and adaptable. M-BAND runs autonomously for up to 30 days, continuously analyzing air samples for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in aggregate. Also as part of the BAND Program, PositiveID developed, validated and implemented its own biological assays for use on the M-BAND system and research laboratories. (www.PSIDMBA.com).

The M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation. M-BAND has been designed and field tested to operate continuously for 30 days unattended between scheduled services. It also operates using industry gold-standard TaqMan(R) PCR (polymerase chain reaction) chemistry.

William J. Caragol, Chairman and CEO of PositiveID, stated, "We believe M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally. We further believe that M-BAND has significant benefits that set this technology apart and put us in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity."

About PositiveID Corporation OTCBB:PSID)

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.

Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT:

Allison Tomek
561-805-8000
atomek@positiveidcorp.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Wednesday, March 7, 2012

Vermillion (NASDAQ: VRML) Closes up over 125% as NSDAQ's Top Percentage Gainer

New York, New York - March 7, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for molecular diagnostics company, Vermillion, Inc. (NASDAQ: VRML ), gaining 125.56% on the day to close at $ 3.00, up 1.67 on over 10 Million shares. The stock continued its rally in after hours trading.

The stock was NASDAQ's top percentage gainer on a day that NASDAQ closed down over 40 points.

The Company reported news that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has voted to approve an application for a Category 1 CPT code for its OVA1® test, which is designed to help differentiate benign versus malignant ovarian masses.

Vermillion, Inc. (VRML)

Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.

More Info:

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Investor Ideas Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Become an Investorideas.com Member
http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Monday, March 5, 2012

Medical Device Stock Alert; PositiveID (OTCBB: PSID) Trades up over 17% on News

New York, NY- March 5, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for PositiveID Corporation (OTCBB: PSID), a developer of medical technologies for diabetes management. The stock is trading up at $0.1380, up 0.0203 (17.25%)as of 10:29AM EST, on over 500,00 shares.

The Company reported news this morning that it has finalized its first-in-class development of a fully synthetic glucose sensing system to measure glucose levels within the body for people with diabetes. PositiveID and its partner RECEPTORS LLC believe they are the first to develop a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma, which is considered to be a critical step in the development of an artificial pancreas.

Full news: http://www.investorideas.com/ CO/PSID/news/2012/03051.asp
Investorideas.com Newswire

About PositiveID Corporation

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, visit www.PositiveIDCorp.com.

PositiveID Corporation (OTCBB: PSID) is a featured biotech company on Investorideas.com

Visit the company profile: http://www.investorideas.com/CO/PSID/

Get biotech news and stock alerts

http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB: PSID) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile. More info: www.InvestorIdeas.com/About/Disclaimer.asp

and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source – www.Investorideas.com

Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Finalizes First-in-Class Development of a Fully Synthetic Glucose Sensing System, a Critical Component of an Artificial Pancreas

DELRAY BEACH, Fla. - March 5, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today that it has finalized its first-in-class development of a fully synthetic glucose sensing system to measure glucose levels within the body for people with diabetes. PositiveID and its partner RECEPTORS LLC believe they are the first to develop a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma, which is considered to be a critical step in the development of an artificial pancreas.

PositiveID's glucose sensing system is the mission-critical component of its GlucoChip(TM), glucose-sensing microchip for people with diabetes, and is based on PositiveID's Patent No. 7,125,382 for an "Embedded Bio-Sensor System." The Embedded Bio-Sensor System patent covers any bio-sensor system that utilizes radio frequency identification technology and includes a remote transponder in wireless communication with an implantable, passively-powered, on-chip transponder.

PositiveID previously announced it created and demonstrated a continuous glucose sensing system in a model blood plasma matrix, and has now advanced development of the sensing system to respond to glucose levels in human plasma. PositiveID also has a patent pending with the U.S. Patent and Trademark Office covering its invention of the stable and reproducible, closed-cycle continuous glucose-sensing system. PositiveID now has five patents and patents pending surrounding the development of GlucoChip.

William J. Caragol, Chairman and CEO of PositiveID, stated, "The development of a fully implantable glucose sensor is one of the essential requirements for the successful development of an artificial pancreas. We believe that with the combined expertise of Receptors and our strong intellectual property portfolio that surrounds the development of our GlucoChip project, we are well positioned to play a potentially significant role in making an artificial pancreas a reality for people with type 1 diabetes."

More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at $200 billion.

PositiveID also recently announced positive preliminary results from its biotransport research study relating to its GlucoChip. Preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids. PositiveID's first animal studies were designed to test the membrane materials that will be the interface between the glucose sensing device and the in vivo environment by evaluating the ability of glucose to pass through the membrane to the sensing device (glucose transport).

About PositiveID Corporation OTCBB:PSID)

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.

About RECEPTORS LLC

Receptors LLC develops Smart Materials products for laboratory, clinical, industrial hygiene and healthcare use that selectively capture and measure chemical, biochemical and cellular targets from complex biological, environmental or industrial samples. The Company's patented Affinity by Design(TM) platform has broad applicability, ranging from the isolation of disease pathway proteins for drug discovery and production of therapeutic antibodies, to the capture of bacteria and viruses for disinfection and diagnostic purposes. Receptors LLC is a private company based in suburban Minneapolis, Minnesota. For further information please visit http://www.receptorsllc.com.

Statements about PositiveID's future expectations, including the likelihood that PositiveID has finalized its first-in-class development of a fully synthetic glucose sensing system to measure glucose levels within the body for people with diabetes; the likelihood that PositiveID and its partner Receptors LLC are the first to develop a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma, which is considered to be a critical step in the development of an artificial pancreas; the likelihood that the development of a fully implantable glucose sensor is one of the essential requirements for the successful development of an artificial pancreas; the likelihood that with the combined expertise of Receptors and PositiveID's strong intellectual property portfolio that surrounds the development of its GlucoChip project, the companies are well positioned to play a potentially significant role in making an artificial pancreas a reality for people with type 1 diabetes; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete development of GlucoChip; PositiveID's ability to play a potentially significant role in making an artificial pancreas a reality; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT:

Allison Tomek
561-805-8000
atomek@positiveidcorp.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Tuesday, February 28, 2012

Biopharmaceutical Stock Alimera Sciences (NASDAQ:ALIM) Continues Yesterday's Gains; Up Over 70% on News on ILUVIEN

New York, New York – February 28, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert update for Alimera Sciences, Inc. (NasdaqGM: ALIM), following up on yesterday’s gains, with a monster run in the stock today, moving up another 70% on over 3.6 Million shares in morning trading.

The Company reported today on the positive outcome of the Decentralized Procedure (DCP) for ILUVIEN(R) in Europe. The announcement follows the issuance of the Final Assessment Report from the Reference Member State (RMS), the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA), and the agreement of all the Concerned Member States (CMS) that ILUVIEN is approvable.

ILUVIEN is Alimera's sustained release intravitreal implant that releases sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic Diabetic Macular Edema.

According to the Company:

ILUVIEN(R) expected to be the first sustained release pharmaceutical in the European Union to treat diabetic macular edema (DME)
ILUVIEN expected to be indicated for chronic DME considered insufficiently responsive to available therapies

Investorideas.com Newswire

Alimera Sciences, Inc., (NASDAQ:ALIM) based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN, is an intravitreal insert containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is in development for the treatment of DME, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/ Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/ BIS/Stock_List.asp

Become an Investorideas.com Member

http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source - www.Investorideas.com

Biodefense Stock News: Vista Partners Updates Coverage on PositiveID Corporation (OTCBB:PSID); $0.38 Target Price

SAN FRANCISCO - February 28, 2012 - (Investorideas.com Newswire) Vista Partners announced today that it has updated coverage on PositiveID Corporation (OTCBB: PSID) ("The Company" or "PSID"); and revised its twelve month target price to $0.38. Ross Silver, Principal Analyst at Vista Partners stated, "The Company's MicroFluidic Systems subsidiary is attempting to secure a portion of the $3.1B Homeland Defense BioWatch pathogen detection contract. The Company is jointly demonstrating its M-BAND device with The Boeing Company and Hamilton Sundstrand at a bioterrorism conference this week." Mr. Silver continues, "We believe the Company's diabetes management products; both FDA approved and under clinical development, could become standards of care. The Company has entered into a partnership with IDEAL LIFE, Inc., a health management leader, to bring iglucose to market. IDEAL LIFE will market iglucose to its large network of customers, including insurance companies, hospitals, and other health care providers. By partnering with IDEAL LIFE, the Company hopes to accelerate market adoption of iglucose. The company anticipates iglucose to be commercially available in the first half of 2012."

To download a FREE copy of the PositiveID Corporation research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com.

Contact:

877.215.4813 or info@vistapglobal.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Monday, February 27, 2012

Biopharmaceutical Stock to Watch; Alimera Sciences (NASDAQ:ALIM) Gains over 35%

New York, New York – February 27, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Alimera Sciences, Inc. (NasdaqGM: ALIM), trading up at $2.3092, gaining 0.5992 or (35.04%) as of 1:22PM EST on over 800,000 shares.

The Company announced Friday that Dan Myers, president and chief executive officer, will present at the Citi 2012 Global Health Care Conference at 1:30 P.M. ET on Wednesday, February 29, 2012 at The Waldorf Astoria Hotel in New York City.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN, is an intravitreal insert containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is in development for the treatment of DME, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Become an Investorideas.com Member
http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com